Literature DB >> 25938977

Effect of ebosin on modulating interleukin-1β-induced inflammatory responses in rat fibroblast-like synoviocytes.

Yang Zhang1, Lifei Wang1, Liping Bai1, Rong Jiang1, Lianhong Guo1, Jianbo Wu1, Guifang Cheng2, Ren Zhang3, Yuan Li1.   

Abstract

The interleukin-1β-mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways are involved in the pathogenesis of rheumatoid arthritis. Ebosin, a novel exopolysaccharide (EPS), exhibits anti-inflammatory activity in rat collagen-induced arthritis by suppressing the production of tumor necrosis factor-α, interleukin-6 and interleukin-1β. The aim of the present study was to assess the effects of ebosin on NF-κB and MAPK signaling pathways mediated through interleukin-1β in rat fibroblast-like synoviocytes (FLSs). Western blotting showed decreased production of phosphorylated p38, JNK1, JNK2, IKKα, IKKβ and IκB in the cytoplasm and NF-κB in the nucleus upon ebosin treatment. The DNA-binding activity of NF-κB in the cell nucleus was also inhibited by ebosin treatment, as demonstrated using an electrophoresis mobility gel shift assay. Analysis of the results of the immunofluorescence assay also showed a reduced amount of NF-κB in the nucleus of cells affected by ebosin. These results provided evidence for the effects of ebosin on both interleukin-1β-mediated MAPK and NF-κB signaling pathways in rat FLSs. In addition, enzyme-linked immunosorbent assay demonstrated that ebosin reduces the levels of matrix metalloproteinases MMP-1 and MMP-3 and the chemokines, interleukin-8 and RANTES. Thus, the results of the present study provide further evidence for understanding the medicinal activity of ebosin at a molecular level, therefore nominating this EPS as a potential therapeutic candidate for the treatment of rheumatic arthritis.Cellular & Molecular Immunology advance online publication, 4 May 2015; doi:10.1038/cmi.2015.36.

Entities:  

Year:  2015        PMID: 25938977      PMCID: PMC5037274          DOI: 10.1038/cmi.2015.36

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  5 in total

1.  Ebosin: a potential therapeutic agent for rheumatoid arthritis and autoinflammatory syndromes.

Authors:  Yang Zhang; Lifei Wang; Yuan Li
Journal:  Cell Mol Immunol       Date:  2017-09-18       Impact factor: 11.530

2.  TXNDC5 synergizes with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts in rheumatoid arthritis through NF-κB signaling.

Authors:  Lin Wang; Hongyan Dong; Guanhua Song; Rui Zhang; Jihong Pan; Jinxiang Han
Journal:  Cell Mol Immunol       Date:  2017-06-26       Impact factor: 11.530

3.  Trichomicin Suppresses Colorectal Cancer via Comprehensive Regulation of IL-6 and TNFα in Tumor Cells, TAMs, and CAFs.

Authors:  Xi Zhao; Xiaoqiang Qi; Wenrui Lian; Xin Tong; Hua Wang; Liya Su; Ping Wei; Zhuochen Zhuang; Jianhua Gong; Liping Bai
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

4.  Ebosin Attenuates the Inflammatory Responses Induced by TNF-α through Inhibiting NF-κB and MAPK Pathways in Rat Fibroblast-Like Synoviocytes.

Authors:  Yang Zhang; Lifei Wang; Liping Bai; Rong Jiang; Jianbo Wu; Yuan Li
Journal:  J Immunol Res       Date:  2022-03-17       Impact factor: 4.818

5.  Screening of Microbial Natural Products and Biological Evaluation of Trichomicin as Potential Anti-Cytokine Storm Agents.

Authors:  Yu Chen; Zhuochen Zhuang; Jing Yang; Liping Bai
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.